Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dyspareunia Clear all
Completed Not applicable Interventional

Life-Stress Interview for Women With Chronic Urogenital Pain Conditions

NCT02286115
View directory record Official record
Conditions
Chronic Urogenital Pain
Interventions
Life-Stress Interview
Behavioral
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 24, 2026, 9:05 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

NCT03986944
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
107
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 24, 2026, 9:05 PM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

NCT02253173
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
Interventions
Estradiol, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Huntsville, Alabama • Montgomery, Alabama • Mesa, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting Not applicable Interventional

Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy

NCT06059586
View directory record Official record
Conditions
Dyspareunia, Pelvic Pain, Sexual Dysfunction, Radiation Toxicity
Interventions
Pelvic health therapy, Dilator feasability
Behavioral · Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Avon, Indiana • Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Active, not recruiting No phase listed Observational

Prospective on Market Patient-reported Outcomes for Milli

NCT06397885
View directory record Official record
Conditions
Vaginismus, Dyspareunia
Interventions
Milli Vaginal Dilator
Device
Lead sponsor
Materna Medical
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting Phase 2 Interventional

Topical Ketotifen 0.25% for Secondary Vestibulodynia

NCT07257029
View directory record Official record
Conditions
Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia, Vulvary Pain Disorders, Neuroproliferative Vestibulodynia, Mast Cell-mediated Neuroinflammation, Instertional Dyspareunia
Interventions
Ketotifen Fumarate 0.25% Cream, Placebo (Vehicle Cream)
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rapidly Absorbing Polyglactin 910 Versus Poliglecaprone 25 for Laceration Repair

NCT03184077
View directory record Official record
Conditions
Dyspareunia, Perineal Tear, Sutured Laceration
Interventions
Laceration Repair with Polyglactin 910, Laceration Repair with poliglecaprone 25
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Not applicable Interventional

Acupuncture for Vulvodynia: A Pre-pilot Study

NCT02704234
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis, Dyspareunia, Pain
Interventions
Active Acupuncture, Placebo Acupuncture
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Wilmette, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting Phase 4 Interventional

Postpartum Vaginal Estrogen for Breastfeeding Patients

NCT05457972
View directory record Official record
Conditions
Breastfeeding, Postpartum Sexual Dysfunction, Vaginal Atrophy
Interventions
Estradiol, Vaginal Moisturizer
Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors

NCT03257670
View directory record Official record
Conditions
Dyspareunia
Interventions
4% Topical Lidocaine Gel, CO2RE fractional laser therapy
Drug · Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 4 Interventional

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
View directory record Official record
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Mollie Study, a Study to Evaluate the Safety and Efficacy of the Mollie Medical Device

NCT05445115
View directory record Official record
Conditions
Dyspareunia
Interventions
Mollie device
Device
Lead sponsor
JSP Innovations
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 4 Interventional

A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction

NCT03199534
View directory record Official record
Conditions
Pelvic Pain, Dyspareunia, Pelvic Floor Dysfunction
Interventions
Botulinum toxin A 50u, Botulinum toxin A 100u, Botulinum toxin A 150u
Drug
Lead sponsor
EvergreenHealth
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 24, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

NCT03682601
View directory record Official record
Conditions
Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions
5% sinecatechins ointment, Placebo, 10% sinecatechins ointment
Drug
Lead sponsor
GTO Pharmaceutical, LLC
Other
Eligibility
20 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
New York, New York • Nyack, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Early Phase 1 Interventional Results available

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

NCT01697345
View directory record Official record
Conditions
Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
Interventions
Testosterone
Drug
Lead sponsor
Creighton University
Other
Eligibility
50 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting Not applicable Interventional

VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia

NCT06840314
View directory record Official record
Conditions
Genito-Pelvic Pain/Penetration Disorder, Dyspareunia, Vaginismus, Pelvic Pain, Vestibulodynia, Vulvodynia (Chronic Vulvar Pain)
Interventions
Pelvic floor therapy
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Not applicable Interventional Results available

Effect of Acupuncture on Patient Vulvodynia Outcomes

NCT03364127
View directory record Official record
Conditions
Vulvodynia, Vulvodynia, Generalized, Vulvar Vestibulitis
Interventions
Active Acupuncture, Placebo Acupuncture
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

NCT00196378
View directory record Official record
Conditions
Menopause
Interventions
Synthetic Conjugated estrogens, B, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

VEDA Study (DHEA vs Estradiol)

NCT07574216
View directory record Official record
Conditions
Post-menopause, Pre-menopause, Sexual Function, Menopause, Vaginal Dryness, Painful Intercourse
Interventions
DHEA ovals, Estradiol 0.01% Vag Cream
Drug
Lead sponsor
University of Arizona
Other
Eligibility
40 Years to 90 Years · Female only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 4 Interventional

Dilators for Dyspareunia Prevention

NCT01299363
View directory record Official record
Conditions
Post-operative Dyspareunia
Interventions
Dilator use
Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

NCT00318500
View directory record Official record
Conditions
Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
49
States / cities
Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Sep 24, 2026, 9:05 PM EDT
Not listed Phase 4 Interventional

Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

NCT02022722
View directory record Official record
Conditions
Dyspareunia
Interventions
Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride, Pelvic Rehabilitation
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2013 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

NCT01539317
View directory record Official record
Conditions
Vulvodynia, Dyspareunia, Breast Cancer, Menopause
Interventions
Topical liquid lidocaine, Topical saline
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 24, 2026, 9:05 PM EDT